YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Tandem Diabetes Care, Inc. TNDM is expanding its product roadmap with new integrations, broader device compatibility and next-generation closed-loop technology. The company's international expansion is driving sales growth and increasing d…
Tandem Diabetes Care has recently launched its Tandem Mobi automated insulin delivery system in 12 countries across Europe and Israel, using Dexcom G7 continuous glucose monitoring and Control-IQ+ technology to automatically adjust insulin…
Tandem Mobi, the world's smallest, durable insulin delivery system, now shipping in multiple international markets. MILAN, September 28, 2026--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabe…
Surgery Partners, 10x Genomics, QuidelOrtho, Zimmer Biomet, and Tandem Diabetes Stocks Trade Down, What You Need To Know What Happened? A number of stocks fell in the afternoon session after sentiment in the healthcare sector weakened, as…
3 Cash-Burning Stocks with Questionable Fundamentals Rapid spending isn't always a sign of progress. Some cash-burning businesses fail to convert investments into meaningful competitive advantages, leaving them vulnerable. Not all companie…
Tandem Diabetes Care, Inc. TNDM shares rallied 7.7% in the last trading session to close at $17.53. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the…
Tandem Diabetes Care, Inc. TNDM is well-positioned to grow in the coming quarters driven by the expanding product choices. The company's pay-as-you-go reimbursement model could lower upfront barriers for pump starts and support higher supp…
An updated edition of the July 6, 2026, article. The world's population is aging rapidly, reshaping how healthcare systems, corporations and investors approach long-term growth opportunities. According to the July 2026 data from the World…
Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. The U.S. Food and Drug Administration (FDA) on Tuesday approved Abbott Laboratories' Libre Duo 10 Day Continuous Dual Glucose Ketone Monit…
Unpacking Q2 Earnings: Hims & Hers Health (NYSE:HIMS) In The Context Of Other Healthcare Technology Stocks Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let's have a look at Hims…
The U.S. Food and Drug Administration (FDA) on Tuesday approved Abbott Laboratories' (NYSE:ABT) Libre Duo 10 Day Continuous Dual Glucose Ketone Monitoring System for diabetes patients aged two and older. The regulatory nod makes the device…
3 Reasons TNDM is Risky and 1 Stock to Buy Instead Over the last six months, Tandem Diabetes's shares have sunk to $22.45, producing a disappointing 13.7% loss - a stark contrast to the S&P 500's 10.5% gain. This might have investors conte…
Insulet Corporation PODD delivered a second-quarter earnings and revenue beat, supported by double-digit Omnipod growth and wider adjusted margins. The stronger quarter, however, came alongside a lower 2026 revenue-growth outlook. That res…
Nvidia initiated, Teradyne downgraded: Wall Street's top analyst calls The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled…
Reflecting On Healthcare Technology Stocks' Q2 Earnings: GoodRx (NASDAQ:GDRX) Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let's have a look at GoodRx (NASDAQ:GDRX) and its peer…
Hims & Hers Health Earnings: What To Look For From HIMS Telehealth company Hims & Hers Health (NYSE:HIMS) will be announcing earnings results this Monday after market hours. Here's what to expect. Hims & Hers Health missed analysts' revenu…
Meridian Funds, managed by ArrowMark Partners, released its second-quarter 2026 investor letter for "Meridian Small Cap Growth Fund". A copy of the letter can be downloaded here. The U.S. market saw a strong rally in the second quarter, fu…
Intuit downgrade, Intuitive Surgical upgraded: Wall Street's top analyst calls The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as…
3 Stocks Under $50 We Steer Clear Of The $10-50 price range often includes mid-sized businesses with proven track records and plenty of growth runway ahead. They also usually carry less risk than penny stocks, though they're not immune to…
3 Healthcare Stocks with Questionable Fundamentals Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Those leading the charge have realized strong financial performance, and ov…
1 Unprofitable Stock with Exciting Potential and 2 Facing Challenges Unprofitable companies can burn through cash quickly, leaving investors exposed if they fail to turn things around. Without a clear path to profitability, these businesse…
In July 2026, Tandem Diabetes Care announced that its t:slim X2 insulin pump with Control-IQ+ technology is now compatible with Abbott's FreeStyle Libre 3 Plus CGM in the UK, Switzerland, Sweden, Finland, and Italy, expanding CGM choice fo…
Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Tandem Diabetes Care (TNDM) is back in focus after announcing that its t:slim X2 insulin pump with Control-IQ+ technolo…
1 of Wall Street's Favorite Stocks with Exciting Potential and 2 We Turn Down Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it's worth remembering…
We recently compiled a list of the 10 Best Innovative Healthcare Stocks to Buy Now. Abbott Laboratories (NYSE:ABT) is one of the best healthcare stocks on our list. TheFly reported on July 6 that Evercore ISI analyst Vijay Kumar reduced th…
Tandem Diabetes Care, Inc. TNDM is well-poised to grow in the coming quarters as the rising prevalence of diabetes and increasing adoption of connected care continue to support demand for automated insulin delivery. The company's pay-as-yo…
Compatibility now available in five countries, with additional markets expected throughout 2026. SAN DIEGO, July 01, 2026--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology compa…
1 Mooning Stock with Impressive Fundamentals and 2 We Find Risky The stocks featured in this article are seeing some big returns. Over the past month, they've outpaced the market due to some combination of positive news, upbeat results, or…
Q1 Earnings Highlights: GoodRx (NASDAQ:GDRX) Vs The Rest Of The Healthcare Technology Stocks As the Q1 earnings season comes to a close, it's time to take stock of this quarter's best and worst performers in the healthcare technology indus…
Thursday, June 11, 2026 The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Mastercard Inc. (MA), Seagate Technology Holdings pl…
It has been about a month since the last earnings report for NeuroPace, Inc. (NPCE). Shares have lost about 0.6% in that time frame, outperforming the S&P 500. But investors have to be wondering, will the recent negative trend continue lea…
For Immediate Release Chicago, IL – June 5, 2026 – Stocks in this week’s article Tandem Diabetes Care, Inc. TNDM, Dell Technologies Inc. DELL and CNO Financial Group CNO. 3 Stocks to Invest In as Broker Rating Upgrades Signal Upside U.S. e…
Tandem Diabetes Care, Inc.’s TNDM appears well positioned for growth, supported by its successful strategic business model transition. The company's expanding international presence is expected to serve as a key growth driver in the coming…
U.S. equities have shown resilience year to date, though gains have been highly uneven. After recovering from early volatility, markets have moved higher as strong corporate earnings, AI-driven optimism and a still-supportive economy have…
Tandem Diabetes TNDM is priced like a company still proving its earnings model. Shares trade at about 1.1x forward 12-month sales, well below the Zacks sub-industry at 3.8x, the Zacks Medical sector at 2.1x, and the S&P 500 at 5.3x. For in…
Tandem Diabetes Care TNDM is pushing two levers at once in 2026: improving operating performance while shifting more U.S. business toward a pharmacy-based, pay-as-you-go pathway. That mix can make near-term comparisons noisy. First-quarter…